ObsEva is a clinical-stage biopharmaceutical company that is solely dedicated to developing and commercializing novel therapeutics for women's reproductive health and pregnancy. Its development pipeline is focused on treating a range of conditions that compromise women's reproductive health, including endometriosis, uterine fibroids, preterm labor, and improving ART outcomes. ObsEva uses a strategic in-licensing approach and a disciplined drug development process to establish a robust pipeline of late-stage clinical development programs.